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Objective: We have previously reported that an HLA 8 of 8
allele-matched unrelated donor (8/8 MUD) is superior to
a related donor with HLA-1 antigen mismatch in the graft-
versus-host (GVH) direction (RD/1AG-MM-GVH) in trans-
plantation for leukemia (Kanda J, et al. Blood 2012). However,
the risk of relapse during the unrelated donor coordination
period biases this comparison. Therefore, we performed
decision analysis of donor selection in allogeneic stem cell
transplantation for acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL) in ﬁrst remission (CR1); this
method can consider various factors including risk of relapse
during the donor coordination period and the decrease in
quality of life (QOL) as a result of chronic graft-versus-host
disease (GVHD).
Methods: The incidences of relapse during the coordination
period of 8/8MUD or RD/1AG-MM-GVH were estimated
using the data from published studies on chemotherapeutic
treatment for AML and ALL. Transition probabilities after
transplantation were estimated using the database of the
Transplant Registry Uniﬁed Management Program for the
Japan Society for Hematopoietic Cell Transplantation. The
expected 5-year survival probabilities with or without QOL
adjustments were estimated using TreeAgePro software.
One-way sensitivity analysis was performed by varying each
transition-probability value within its plausible range.
Results: In transplantation for AML-CR1, the expected 5-year
survival probability was higher on selection of 8/8MUD than
RD/1AG-MM-GVH (59% vs. 47%), and this superiority
remained unchanged by sensitivity analysis of various
factors, including the interval between achievement of CR1
and actually receiving transplantation. In transplantation for
ALL-CR1, the 5-year survival probability was higher on
selection of 8/8 MUD (48% vs. 43%). In one-way sensitivity
analysis, the 5-year survival probability was higher on
selection of RD/1AG-MM-GVH when the interval between
CR1 and 8/8 MUD transplantation was 7 months. However,
8/8 MUD was superior after QOL adjustments. If the 5-year
survival rate was increased by 3% (7% after QOL adjustment)
in transplantation using RD/1AG-MM-GVH, the merit of
selecting RD/1AG-MM-GVH outweighs that of 8/8 MUD.
Conclusions: 8/8MUDshouldbeprioritized in transplantation
for AML-CR1. In transplantation for ALL-CR1, RD/1AG-MM-
GVHshould beprioritized onlywhen the interval between CR1
and 8/8 MUD transplantation is expected to be long. However,
MUD should be prioritized if QOL is considered.476
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gGmbH (IKT), Ulm, GermanyOccurrences of relapse and transplantation related mortality
(TRM) are major complications after allogeneic hematopoi-
etic stem cell transplantation (HSCT). In haploidentical
transplantation, mismatches for inhibitory killer cell immu-
noglobulin-like receptor (KIR)-ligand in GvHD direction have
been shown to be associated with lower rates of relapse.
To investigate a potential effect of NK alloreactivity as pre-
dicted by themissing ligandmodel in the setting of unrelated
transplantation, we investigated 496 patients transplanted
for malignant disorders with single HLA-B or HLA-C mis-
matched donors and T-cell-replete grafts. “Missing ligand”
was deﬁned as absence of a donor KIR ligand HLA-C group 1,2
or HLA-Bw4 allele in the patient in GvH-direction only or in
combined HvG/GvH direction. Overall survival (OS), disease
free survival (DFS), relapse, and treatment related mortality
(TRM)were assessed usingKaplan-Meier analysis, competing
risks regression and extended Cox regression models.
Out of the 496 transplantation pairs, 109 (22.0%) were iden-
tiﬁed as belonging to the “missing ligand”-group, the
remaining 387 (78.0%) were used as a control group. Univar-
iate and multivariate analysis did not show any differences
regarding OS or DFS between the two groups. Univariate
analysis showed no signiﬁcant difference regarding TRM
(31.6% vs. 21.1%, P¼ .13) anda signiﬁcant higher risk for relapse
(29.0% vs. 38.7%, P ¼ .048) in the “missing ligand” group.
Multivariate competing risks regressionshowednosigniﬁcant
difference for TRM (HR 0.76, CI 0.49-1.23, P ¼ .28) and a trend
towards increased rates of relapse (HR 1.49, CI 1.00e 2.20, P¼
.05) for the patients within the “missing ligand” group.
The results of this study do not conﬁrm previous results seen
in haploidentical HSCT. T-cell alloreactivity dominates over
NK cell alloreactivity and leads to a diminished reconstitu-
tion of KIR expression in T-cell-replete grafts and potentially
impaired “licensing” compared to T-cell depleted trans-
plantations. This effect could explain differences between
the haploidentical related and single mismatched unrelated
transplantation.
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Adoptive transfer of T cells directed to tumor-associated
antigens (TAAs) by transgenic expression of chimeric antigen
receptors (CARs) can produce tumor responses, even in
patients with resistant malignancies. However targeting
a single TAA may lead to selection of the nontargeted TAA
population, leading to tumor immune escape. To overcome
this limitation, we have targeted two distinct TAAs, MUC1
and PSCA, both commonly express in pancreatic cancer. We
ﬁrst constructed a CAR targeting MUC1, which coexpressed
a truncated form of CD19 (DCD19) as a selectable marker.
After retroviral transduction, primary T cells stably expressed
both transgenes (834% and 668%, CAR-MUC1 and DCD19,
respectively). CAR-MUC1 T cells were able to speciﬁcally kill
MUC1+ target cell lines, CAPAN1 and DU145, with no
recognition of MUC1- targets, 293T (355%, 234% and
32% speciﬁc lysis, respectively, 10:1 E:T). To further eval-
uate the longer term killing effects, we cultured theseMUC1+
